BlossomHill (BLSM) Director Carl L. Gordon Buys $10M of Stock

What Happened

• Carl L. Gordon, a director of BlossomHill Therapeutics (BLSM), participated in the company's IPO transactions on August 10, 2026. He purchased 625,000 common shares in the IPO at $16.00 per share, spending $10,000,000.
• In addition, Gordon received a total of 2,089,279 common shares (1,039,996 and 1,049,283) through automatic conversions of Series A and Series B preferred stock into common stock upon the closing of the IPO. The conversions were effected without payment (reported as $0) as described in the filing.

Key Details

• Transaction date: August 10, 2026. Form 4 filed: August 12, 2026 (timely within the typical 2-business-day window).
• Purchase: 625,000 shares @ $16.00 = $10,000,000 (IPO purchase; footnote F2).
• Conversions: 1,039,996 and 1,049,283 shares converted from Preferred to Common (automatic conversion at IPO, no consideration paid; footnote F1).
• Shares owned after the transactions: not reported in the summary provided.
• Other footnotes (F3/F4) in the filing concern OrbiMed-related entities and their beneficial-ownership disclaimers; they are institutional disclosures and not part of Gordon’s personal purchase details.

Context

• The derivative entries reflect preferred-stock conversion into common shares at the IPO (not an option exercise requiring cash). The open-market/private-purchase entry here reflects an IPO allocation purchase, which is often viewed as a more informative bullish signal than routine sales because the insider invested $10M of capital. The filing appears timely.